*November 2023* Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer. Listen here.
laurabbook@gmail.comDecember 27, 2023
*December 2023* This new on-demand educational webinar featuring oncology experts (Drs. Balaz Halmos and Julie Rotow) and patient advocates (Ivy Elkins and Jill Feldman) discusses the therapeutic landscape of uncommon EGFR alterations within NSCLC as well as current clinical trials aimed at advancing therapeutic options in this space. Watch video here.
laurabbook@gmail.comDecember 27, 2023
Patient Perspective: Patients With EGFR+ NSCLC May Still Opt for Quality Over Quantity After FLAURA2
*November 2023* Patients want improved efficacy, but not necessarily at the expense of their quality of life. Combination treatment comes with increased toxicities, which make maintaining a normal life more difficult. Even grade 1 side effects such as diarrhea or nausea can make it difficult to hold a job or…
laurabbook@gmail.comDecember 27, 2023
*November 2023* Earlier this month, 15 young EGFR lung cancer investigators from the U.S., along with a panel of expert mentor judges and patient advocates, gathered together for our 5th annual EGFR Resisters Research Summit. Congratulations to the trainee research award winners. Taking 3rd place was Dr. Marie Dreyer with her…
laurabbook@gmail.comDecember 27, 2023
*October 2023* Sandip P. Patel, MD discusses treatment options available for patients with EGFR-mutant NSCLC who progress on EGFR TKIs and platinum-based chemotherapy. Watch video here.
laurabbook@gmail.comDecember 27, 2023
*October 2023* Take home message: Comparison Dato-DXd, a novel TROP2-directed antibody-drug conjugate, to docetaxel in pretreated advanced/metastatic non-small cell lung cancer (NSCLC) patients, revealing significantly improved progression-free survival with Dato-DXd, especially in non-squamous histology patients, while demonstrating a manageable safety profile and ongoing evaluation of overall survival. (From OncoAlert) The Trop-2…
laurabbook@gmail.comDecember 27, 2023
*October 2023* PURPOSE In the treatment of non-small cell lung cancer (NSCLC) with a driver mutation, the role of anti-PD-(L)1 antibody following tyrosine kinase inhibitor (TKI) remains unclear. This randomized, open-label, multicenter, phase 3 study evaluates the efficacy of atezolizumab plus bevacizumab, paclitaxel and carboplatin (ABCP) in EGFR or ALK-mutated NSCLC that progressed…
laurabbook@gmail.comDecember 24, 2023
*October 2023* The European Commission (EC) has approved fam-trastuzumab deruxtecan-nxki (Enhertu) for the treatment of patients with advanced non–small cell lung cancer (NSCLC) whose tumors harbor an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.1 The regulatory decision was supported by data from the phase…
laurabbook@gmail.comDecember 24, 2023
*October 2023* Take home message: Amivantamab in combination with chemotherapy showed significantly improved PFS and a higher response rate compared to chemotherapy alone in treatment-naive patients with advanced non-small-cell lung cancer harboring EGFR exon 20 insertions, demonstrating its efficacy as a first-line treatment. The phase 3 PAPILLON trial (NCT04538664) resulted in…
laurabbook@gmail.comDecember 24, 2023
*October 2023* Osimertinib (Tagrisso) plus chemotherapy reduced the risk of central nervous system (CNS) disease progression or death vs osimertinib alone in patients with locally advanced or metastatic EGFR-positive non–small cell lung cancer (NSCLC) who had brain metastases at baseline, according to data from the phase 3 FLAURA2 trial (NCT04035486) presented…
laurabbook@gmail.comDecember 24, 2023
